The project is designed to generate a robust pipeline of anti-trypanosomatid drugs with product profiles suitable for clinical trials and deployment. It will be conducted by a highly organized Trypanosomatid Drug Development Consortium (TDDC) with extensive and diverse expertise, technical capabilities, facilities, and ongoing studies with these pathogens. The TDDC consortium includes SBRI/University of Washington, UCSF, University of North Carolina at Chapel Hill, and the Eskitis Institute of Griffiths University, each of which has collaborative or consulting ties with various other public and private institutions. The consortium has the essential technologies and equipment, compound and natural product libraries, in vitro and in vivo models, expertise, and project management skills to conduct the project. It will use a milestone based, decision matrix supported, product development approach to: 1) Identify trypanosomatid candidate drug targets by comprehensive literature and informatic analyses and prioritize them for experimental validation and initial assay development. 2) Develop high throughput screens (HTSs) for prioritized targets. The HTSs will use sensitive and specific reporter systems, typically with recombinant proteins, and will be robust, reproducible, and sensitive. 3) Screen selected libraries of synthetic and natural product compounds with these HTSs as well as trypanosomatid cell viability assays. Active compounds in natural product hits will be isolated and their structures determined, and IC50s will be determined for all promising hits. 4) Perform hit-to lead chemistry to provide high-quality lead candidates and iterative lead optimization and SAR analysis using compound analogs. 5) Lead-like compounds will be tested for efficacy and toxicology, ADME, and PK to generate a select set of compounds for clinical analyses. 6) Generate a centralized project and information management system that will be instituted as an information-based interface among the sites and as a community resource. It will facilitate workflow and aid coordination and decision making. The outcome will be a set of targets and chemical entities distributed along the pipeline from target discovery to preclinical validation thus providing a rich ongoing resource of drug candidates for clinical studies.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Project--Cooperative Agreements (U01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-TP-M (M1))
Program Officer
Rogers, Martin J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Seattle Biomedical Research Institute
United States
Zip Code
Demir, Ozlem; Labaied, Mehdi; Merritt, Chris et al. (2014) Computer-aided discovery of Trypanosoma brucei RNA-editing terminal uridylyl transferase 2 inhibitors. Chem Biol Drug Des 84:131-9
Pham, Ngoc B; Deydier, Sophie; Labaied, Mehdi et al. (2014) N¹,N¹-Dimethyl-N³-(3-(trifluoromethyl)phenethyl)propane-1,3-diamine, a new lead for the treatment of human African trypanosomiasis. Eur J Med Chem 74:541-51
Merritt, Christopher; Stuart, Kenneth (2013) Identification of essential and non-essential protein kinases by a fusion PCR method for efficient production of transgenic Trypanosoma brucei. Mol Biochem Parasitol 190:44-9
Abdulla, Maha-Hamadien; Bakhiet, Moiz; Lejon, Veerle et al. (2013) TLTF in cerebrospinal fluid for detection and staging of T. b. gambiense infection. PLoS One 8:e79281
Mashiyama, Susan T; Koupparis, Kyriacos; Caffrey, Conor R et al. (2012) A global comparison of the human and T. brucei degradomes gives insights about possible parasite drug targets. PLoS Negl Trop Dis 6:e1942
Navarro, Gabriel; Chokpaiboon, Supchar; De Muylder, Geraldine et al. (2012) Hit-to-lead development of the chamigrane endoperoxide merulin A for the treatment of African sleeping sickness. PLoS One 7:e46172
Parsons, Marilyn; Myler, Peter J; Berriman, Matthew et al. (2011) Identity crisis? The need for systematic gene IDs. Trends Parasitol 27:183-4
Mackey, Zachary B; Koupparis, Kyriacos; Nishino, Mari et al. (2011) High-throughput analysis of an RNAi library identifies novel kinase targets in Trypanosoma brucei. Chem Biol Drug Des 78:454-63
Holla, Harish; Labaied, Mehdi; Pham, Ngoc et al. (2011) Synthesis of antitrypanosomal 1,2-dioxane derivatives based on a natural product scaffold. Bioorg Med Chem Lett 21:4793-7
Goldsmith, Rachel Beaulieu; Gray, Danny R; Yan, Zhixia et al. (2010) Application of monoclonal antibodies to measure metabolism of an anti-trypanosomal compound in vitro and in vivo. J Clin Lab Anal 24:187-94

Showing the most recent 10 out of 13 publications